Manipulating The Androgen Axis | Radionuclide Therapy And Bone Health

This educational series is supported by independent educational grants from: AbbVie, Astellas and Pfizer, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Genomic Health, Merck, Sanofi Genzyme Episode 3: Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents and Radionuclide Therapy and Bone Health Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents David F. Jarrard, MD Radionuclide Therapy and Bone Health Steve Boorjian, MD CME Available: auau.auanet.org/node/25405 The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer. Based on the documented need for additional education in this area, the AUA in collaboration with Society of Urologic Oncology (SUO) has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists. To extend the educational reach, the AUA will capture the live presentations and develop three podcasts with a faculty interview segment.